Products for Research Use Only

AH1

CAT: 0804-HY-P4193-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P4193-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AH1 is a MHC class I-restricted tumor-specific antigenic peptide that can be presented by the murine MHC class I molecule Ld. AH1 is derived from the envelope protein (gp70) of the endogenous ecotropic murine leukemia virus (MuLV) in mice. AH1 acts as an immunodominant CTL epitope in CT26 colon carcinoma. Additionally, AH1 is also an immunodominant CTL target for TS/A murine mammary adenocarcinoma, and its specific CTLs can mediate the killing and rejection of this tumor[1][2].
CAS Number
181272-91-3
UNSPSC
12352209
Target
MHC
Type
Peptides
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ah1.html
Purity
99.16
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)CC3=CN=CN3)=O)CC4=CC=C(C=C4)O)=O)=O)NC([C@H](CO)NC([C@H]5N(CCC5)C([C@@H](N)CO)=O)=O)=O
Molecular Formula
C54H70N12O15
Molecular Weight
1127.21
References & Citations
[1]M Toda, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10;10 (3) :385-93.|[2]Antonio Rosato, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res. 2003 May 1;63 (9) :2158-63.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N11543-01AH13

Popular Products